Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telmisartan + amlodipine + rosuvastatin (Yuhan, 044984)
- Development stage
- Phase 3
- Lead developer
- Yuhan
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
YHP1604 is a fixed-dose combination (FDC) therapy developed by Yuhan Corporation for the management of patients with both hypertension and hyperlipidemia. It integrates three active pharmacological agents: telmisartan, an angiotensin II receptor blocker (ARB); amlodipine, a dihydropyridine calcium channel blocker (CCB); and rosuvastatin, an HMG-CoA reductase inhibitor (statin). By combining these three medications into a single tablet, YHP1604 aims to simplify complex treatment regimens, thereby improving patient adherence and clinical outcomes in the management of cardiovascular risk factors. The product was approved in South Korea under the brand name Duowell-A.
- Brand names
- Duowell-A
- Other names
- telmisartan/amlodipine/rosuvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)LTCC (Voltage-gated calcium channel (L-type))PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on telmisartan + amlodipine + rosuvastatin (Yuhan, 044984).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telmisartan + amlodipine + rosuvastatin (Yuhan, 044984).